Technical Analysis for TRVI - Trevi Therapeutics, Inc.

Grade Last Price % Change Price Change
C 3.45 -0.58% -0.02
TRVI closed down 0.58 percent on Thursday, March 28, 2024, on 39 percent of normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Flat

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -0.58%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.58%
Calm After Storm Range Contraction -0.58%
NR7 Range Contraction -0.58%
Narrow Range Bar Range Contraction -0.58%
Inside Day Range Contraction -0.58%
Wide Bands Range Expansion -0.58%
MACD Bearish Signal Line Cross Bearish 1.77%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 14 hours ago
Up 2% about 14 hours ago
Up 1% about 15 hours ago
Down 2 % about 16 hours ago
10 DMA Support about 16 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Trevi Therapeutics, Inc. Description

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Organic Compounds Chemical Compounds Opioids Analgesics Ethers Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Nervous System Morphinans Physiology Cough Phenols Opioid Receptors Parkinson’s Disease Pruritus Dyskinesia Peripheral Nervous System Prurigo Prurigo Nodularis

Is TRVI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.0
52 Week Low 0.9712
Average Volume 297,158
200-Day Moving Average 2.03
50-Day Moving Average 2.42
20-Day Moving Average 3.21
10-Day Moving Average 3.46
Average True Range 0.28
RSI (14) 65.64
ADX 53.47
+DI 26.58
-DI 9.81
Chandelier Exit (Long, 3 ATRs) 3.17
Chandelier Exit (Short, 3 ATRs) 3.45
Upper Bollinger Bands 3.75
Lower Bollinger Band 2.67
Percent B (%b) 0.73
BandWidth 33.73
MACD Line 0.29
MACD Signal Line 0.32
MACD Histogram -0.026
Fundamentals Value
Market Cap 220.31 Million
Num Shares 63.9 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -15.68
Price-to-Sales 0.00
Price-to-Book 1.17
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.68
Resistance 3 (R3) 3.68 3.61 3.64
Resistance 2 (R2) 3.61 3.55 3.61 3.62
Resistance 1 (R1) 3.53 3.52 3.50 3.53 3.61
Pivot Point 3.46 3.46 3.44 3.46 3.46
Support 1 (S1) 3.38 3.40 3.35 3.38 3.29
Support 2 (S2) 3.31 3.37 3.31 3.28
Support 3 (S3) 3.23 3.31 3.26
Support 4 (S4) 3.23